Generic makers in India rethink semaglutide prices, eye $36 to $60 range
Generic drugmakers in India are revising pricing plans after Denmark’s Novo Nordisk (NOV: N) slashed costs for its weight-loss injection Wegovy (semaglutide). Companies that had aimed to launch generics at $84 to $96 per month are now considering a lower $36 to $60 per month range.
Earlier this month, Novo Nordisk cut Wegovy prices by 20% to 37% to fend off Eli Lilly’s (NYSE: LLY) rival Mounjaro (tirzepatide).
A month’s supply of four injections now costs $131 per month for the starter dose (0.25mg) and $198 per month for higher doses (1.7mg and 2.4mg), sources in the industry pointed out.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
| Headless Content Management with Blaze